Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy.

EBioMedicine - 1 Dec 2020

Li Ziteng, Chen Siyuan, Feng Wanjing, Luo Yixiao, Lai Hongyan, Li Qin, Xiu Bingqiu, Li Yuchen, Li Yan, Huang Shenglin, Zhu Xiaodong

Abstract excerpt

BACKGROUND: The prevalence of HER2 alterations in pan-cancer indicates a broader range of application of HER2-targeted therapies; however, biomarkers for such therapies are still insufficient and limited to breast cancer and gastric cancer. METHODS: Using multi-omics data from The Cancer Genome Atlas (TCGA), the landscape of HER2 alterations was exhibited across 33 tumor types. A HER2 index was constructed using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Susceptibility

Share to Gene Amplification

Share to Machine Learning

Share to Molecular Targeted Therapy

Share to Proteomics

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33161227
DOI: 10.1016/j.ebiom.2020.103074
PMCID: PMC7670125

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy.PMID 33161227Read ↗

iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics dataSemantic proximity Read ↗

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.Semantic proximity Read ↗

Combined Hormone Receptor and Human Epidermal Growth Factor Receptor-2 Expression Reflects Inter-and Intra-tumor Heterogeneity in Hormone Receptor-positive/human Epidermal Growth Factor Receptor-2-positive Breast CancerSemantic proximity Read ↗

“Omics” of HER2-Positive Breast CancerSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtypeSemantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancerSemantic proximity Read ↗

Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients.Semantic proximity Read ↗

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.Semantic proximity Read ↗

Tumor Mutational Landscape and Its Correlation with Histopathological Characteristics in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.